Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Avantium NV | 8 |
| 2 | Eli Lilly and Co | 6 |
| 3 | Goodyear Tire and Rubber Co | 5 |
| 4 | China National Tobacco Corp | 3 |
| 5 | Disco Corp | 3 |
| 6 | Chinese Academy of Sciences | 2 |
| 7 | Kissei Pharmaceutical Co Ltd | 2 |
| 8 | Suntory Holdings Ltd | 2 |
| 9 | The University of Texas System | 2 |
| 10 | Arakawa Chemical Industries Ltd | 1 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 33 |
| 2 | A61K | Medicinal preparations | 28 |
| 3 | C07D | Heterocyclic compounds | 20 |
| 4 | C08K | Polymer compositions (additives) | 9 |
| 5 | Y02P | Climate change mitigation: production | 9 |
| 6 | C07B | General methods of organic chemistry | 7 |
| 7 | B01J | Chemical/physical processes (e.g. catalysts) | 5 |
| 8 | B60C | 5 | |
| 9 | C07C | Acyclic and carbocyclic compounds | 5 |
| 10 | C08L | Polymer compositions (blends) | 5 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Application of 5-methoxyflavone in preparing medicine for treating obesity, hypercholesterolemia and fatty liver | 2022 | 2 | |
| Application of 5-methoxyflavone in preparation of medicine for preventing or treating influenza virus infection | 2022 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Janez Konc | University of Ljubljana | 2 |
| 2 | Vijaykumar Sayeli | Mamata Medical College | 2 |
| 3 | Stanislav Gobec | University of Ljubljana | 2 |
| 4 | Thomas Walle | Medical University of South Carolina | 2 |
| 5 | S. Viswanathan | Meenakshi Academy of Higher Education and Research | 2 |
| 6 | Binoy Varghese Cheriyan | Vels University | 2 |
| 7 | Jure Stojan | University of Ljubljana | 2 |
| 8 | Jagan Nadipelly | Texila American University | 2 |
| 9 | Tea Lanišnik Rižner | University of Ljubljana | 2 |
| 10 | Parimala Kathirvelu | Meenakshi Academy of Higher Education and Research | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Antagonism of Aryl Hydrocarbon Receptor Signaling by 6,2′,4′-Trimethoxyflavone | 2009 | 79 | Toxic Organic Pollutants Impact |
| 5-Methoxyflavone-induced AMPKα activation inhibits NF-κB and P38 MAPK signaling to attenuate influenza A virus-mediated inflammation and lung injury in vitro and in vivo | 2022 | 46 | Peroxisome Proliferator-Activated Receptors |
| Identification of 5-Methoxyflavone as a Novel DNA Polymerase-Beta Inhibitor and Neuroprotective Agent against Beta-Amyloid Toxicity | 2015 | 28 | Alzheimer's disease research and treatments |
| Anti-inflammatory activity of 4′,6,7-trihydroxy-5-methoxyflavone from Fridericia chica (Bonpl.) L.G.Lohmann | 2018 | 27 | Natural product bioactivities and synthesis |
| Phytoestrogens as inhibitors of fungal 17β-hydroxysteroid dehydrogenase | 2005 | 26 | Estrogen and related hormone effects |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of 5-methoxy-2-phenylchromen-4-one?
Which organizations hold the most patents for 5-methoxy-2-phenylchromen-4-one?
What is the trend in patent filings for this compound in recent years?
What biological activities have been studied for 5-methoxy-2-phenylchromen-4-one?
What are the primary patent classification areas for this compound?